Dr Kirstine Bell is a Senior Research Fellow at the University of Sydney and is the Principal Research Fellow leading the Australian Type 1 Diabetes National Screening Pilot and co-first author on the 2022 ISPAD Clinical Practice Consensus Guideline: Stages of type 1 diabetes in children and adolescents.

Braden Engelbogen is a third year basic physician trainee at the Royal Melbourne Hospital with aspirations to work in endocrinology. His clinical interests include inpatient initiatives for managing diabetes and osteoporosis, with research in diabetic technology and endocrinological emergencies.

Jen Snaith is a Staff Specialist Endocrinologist at St Vincent’s Hospital Sydney. She is a UNSW PhD candidate and a recipient of the NHMRC post-graduate scholarship, co-funded by Diabetes Australia. She conducted the INTIMET study, a randomised controlled clinical trial examining the impact of metformin on insulin resistance.

Dr An Tran-Duy is a Senior Research Fellow at Melbourne School of Population Health, University of Melbourne. His research interests include prediction and simulation of disease progression and health outcomes for chronic diseases including diabetes. He co-leads the Health Economics Platform at the Australian Centre for Accelerating Diabetes Innovations (ACADI).

Glenn Ward BSC, MBBS, D Phil(Oxon), FRACP, FRCPath, is Deputy Director of Endocrinology, Head of Diabetes, Clinical Consultant in Biochemistry, and Honorary Research Fellow in the Bionics Institute at St Vincent’s Hospital Melbourne. Appointed Associate Professor of Pathology in 2001, and Endocrinologist, Australian Islet Transplant Program since 2006 .

John Wentworth is an adult endocrinologist whose research aims to diagnose type 1 diabetes early and preserve beta cell function with immunotherapy. He established the Type1Screen family screening program in 2019 and leads the ATIC collaborative working to develop and implement preventative immunotherapy for type 1 diabetes.

John Wentworth is an endocrinologist working at Royal Melbourne Hospital and Walter and Eliza Hall Institute. He leads the Australasian T1D Immunotherapy Collaborative (ATIC) and the Type1Screen national autoantibody screening program for type one families.

Dr Linda Wu is a clinical Endocrinologist and current PhD Candidate based at the Westmead Institute for Medical Research. Her area of interest in particular involves checkpoint inhibitor related autoimmune diabetes including clinical research and animal models to investigate this disease.